IMMU - イミュノメディクス (Immunomedics Inc.) イミュノメディクス

 IMMUのチャート


 IMMUの企業情報

symbol IMMU
会社名 Immunomedics Inc. (イミュノメディクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 イミュノメディックス(Immunomedics Inc.)は癌、自己免疫疾患及び他の重篤な疾患の治療用のモノクローナル抗体ベースの製品の開発に集中するバイオ医薬品会社である。同社は地理的な事業は米国と欧州を含む。同社の技術は、非標識または裸の形で単独で、または放射性同位体、化学療法剤、サイトカインまたは毒素と結合して使用できるヒト化抗体を作製することを可能にする。同社は8つの臨床段階の製品候補のパイプラインを有する。その治験薬のポートフォリオには、化学療法薬のペイロードを腫瘍に直接送達するように設計された抗体 - 薬物コンジュゲート(ADC)が含まれ、これらの化学療法薬の従来の投与で見出される全体的な毒性効果を管理する。そのADCは、第II相試験中のsacituzumab govitecan(IMMU-132)およびlabetuzumab govitecan(IMMU-130)である。   イミュノメディクスは、米国のバイオ製薬会社。癌、自己免疫疾患の治療のために、モノクロ―ナル抗体をベ―スとした製品を開発。製品候補には、CD22を標的とするヒト化抗体エプラツズマブがある。CD22は、Bリンパ球の表面に見出される抗原、白血球の種類である。また、膵臓癌患者の治療に、イットリウム-90標識クリバツズマブ・テトラキセタンを開発。   Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.
本社所在地 300 The American Road Morris Plains NJ 07950 USA
代表者氏名 Behzad Aghazadeh Behzad Aghazadeh
代表者役職名 Independent Chairman of the Board
電話番号 +1 973-605-8200
設立年月日 30133
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 185人
url www.immunomedics.com
nasdaq_url https://www.nasdaq.com/symbol/immu
adr_tso
EBITDA EBITDA(百万ドル) -139.75000
終値(lastsale) 20.01
時価総額(marketcap) 3738508540.11
時価総額 時価総額(百万ドル) 4474.626
売上高 売上高(百万ドル) 2.15600
企業価値(EV) 企業価値(EV)(百万ドル) 3855.58701
当期純利益 当期純利益(百万ドル) -273.83690
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Immunomedics Inc. revenues decreased 30% to $2.2M. Net loss increased 79% to $273.8M. Revenues reflect Europe segment decrease of 39% to $1.5M. Higher net loss reflects Research and development - Balancing val increase of 97% to $96.9M (expense) Changes in fair market value of warrant increase of 78% to $108.6M (expense).

 IMMUのテクニカル分析


 IMMUのニュース

   Head to Head Analysis: OncoCyte (NYSE:OCX) & Immunomedics (NYSE:IMMU)  2020/10/24 05:10:46 Dispatch Tribunal
OncoCyte (NYSE:OCX) and Immunomedics (NASDAQ:IMMU) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership. Profitability This table compares OncoCyte and Immunomedics’ net margins, return on equity and return on assets. Net Margins […]
   Gilead Sciences Closes Immunomedics Purchase  2020/10/23 15:47:35 The Street
The two companies announced the $21 billion acquisition last month.
   Gilead Sciences Completes Acquisition of Immunomedics, Inc.  2020/10/23 13:15:00 Business Wire
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (Nasdaq: IMMU) for approximately $21 billion in the aggregate. “We are very pleased to reach today’s milestone and to welcome the talented Immunomedics team to the Gilead family. There is a lot of important work ahead of us to deliver on the vast potential that Trodelvy offers for patients with cancer,” said Daniel O’Day,
   The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO  2020/10/23 11:26:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Kodiak Sciences Inc (NASDAQ: KOD ) Nevro Corp (NYSE: NVRO ) Praxis Precision Medicines Inc (NASDAQ: PRAX ) Repligen Corporation (NASDAQ: RGEN ) Replimune Group Inc (NASDAQ: REPL ) (priced its common stock offering of 4.69 million shares at $40 apiece. Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 22) Artelo Biosciences Inc (NASDAQ: ARTL ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Aziyo Biologics Inc (NASDAQ: AZYO ) DBV Technologies ADR Representing 0.5 Ord Shs (NASDAQ: DBVT ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its $15 million worth of common stock offering) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Metacrine Inc (NASDAQ: MTCR ) Rockwell Medical Inc (NASDAQ: RMTI ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) Stocks In Focus Akebia Presents Positive Phase 3 Data For Anemia Drug In Chronic Kidney Disease Patients Akebia Therapeutics Inc (NASDAQ: AKBA ) presented at the American Society of Nephrology Kidney Week 2020 Reimagined, …
   The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings  2020/10/21 12:04:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20) Aileron Therapeutics Inc (NASDAQ: ALRN ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI )( announced a reverse merger with Cytocom) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Insmed Incorporated (NASDAQ: INSM ) Laboratory Corp. of America Holdings (NYSE: LH ) Pacific Biosciences of California Inc (NASDAQ: PACB ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 19) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Alector Inc (NASDAQ: ALEC ) Aligos Therapeutics Inc (NASDAQ: ALGS ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Baudax Bio Inc (NASDAQ: BXRX ) (issued a corporate update) Codiak BioSciences Inc (NASDAQ: CDAK ) (listed on Nasdaq on Oct. 14) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) ProQR Therapeutics NV (NASDAQ: PRQR ) Titan Pharmaceuticals, Inc (NASDAQ: TTNP ) Stocks In Focus Prothena to Advance Parkinson's Disease Drug Into Large-scale Confirmatory Study Prothena Corporation PLC (NASDAQ: PRTA ) said, based on positive signals of efficacy consistent with disease modification in the PASADENA study, it along with Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ) plans …
   Head to Head Analysis: OncoCyte (NYSE:OCX) & Immunomedics (NYSE:IMMU)  2020/10/24 05:10:46 Dispatch Tribunal
OncoCyte (NYSE:OCX) and Immunomedics (NASDAQ:IMMU) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership. Profitability This table compares OncoCyte and Immunomedics’ net margins, return on equity and return on assets. Net Margins […]
   Gilead Sciences Closes Immunomedics Purchase  2020/10/23 15:47:35 The Street
The two companies announced the $21 billion acquisition last month.
   Gilead Sciences Completes Acquisition of Immunomedics, Inc.  2020/10/23 13:15:00 Business Wire
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (Nasdaq: IMMU) for approximately $21 billion in the aggregate. “We are very pleased to reach today’s milestone and to welcome the talented Immunomedics team to the Gilead family. There is a lot of important work ahead of us to deliver on the vast potential that Trodelvy offers for patients with cancer,” said Daniel O’Day,
   The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO  2020/10/23 11:26:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Kodiak Sciences Inc (NASDAQ: KOD ) Nevro Corp (NYSE: NVRO ) Praxis Precision Medicines Inc (NASDAQ: PRAX ) Repligen Corporation (NASDAQ: RGEN ) Replimune Group Inc (NASDAQ: REPL ) (priced its common stock offering of 4.69 million shares at $40 apiece. Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 22) Artelo Biosciences Inc (NASDAQ: ARTL ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Aziyo Biologics Inc (NASDAQ: AZYO ) DBV Technologies ADR Representing 0.5 Ord Shs (NASDAQ: DBVT ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its $15 million worth of common stock offering) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Metacrine Inc (NASDAQ: MTCR ) Rockwell Medical Inc (NASDAQ: RMTI ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) Stocks In Focus Akebia Presents Positive Phase 3 Data For Anemia Drug In Chronic Kidney Disease Patients Akebia Therapeutics Inc (NASDAQ: AKBA ) presented at the American Society of Nephrology Kidney Week 2020 Reimagined, …
   The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings  2020/10/21 12:04:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20) Aileron Therapeutics Inc (NASDAQ: ALRN ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI )( announced a reverse merger with Cytocom) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Insmed Incorporated (NASDAQ: INSM ) Laboratory Corp. of America Holdings (NYSE: LH ) Pacific Biosciences of California Inc (NASDAQ: PACB ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 19) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Alector Inc (NASDAQ: ALEC ) Aligos Therapeutics Inc (NASDAQ: ALGS ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Baudax Bio Inc (NASDAQ: BXRX ) (issued a corporate update) Codiak BioSciences Inc (NASDAQ: CDAK ) (listed on Nasdaq on Oct. 14) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) ProQR Therapeutics NV (NASDAQ: PRQR ) Titan Pharmaceuticals, Inc (NASDAQ: TTNP ) Stocks In Focus Prothena to Advance Parkinson's Disease Drug Into Large-scale Confirmatory Study Prothena Corporation PLC (NASDAQ: PRTA ) said, based on positive signals of efficacy consistent with disease modification in the PASADENA study, it along with Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ) plans …
   Head to Head Analysis: OncoCyte (NYSE:OCX) & Immunomedics (NYSE:IMMU)  2020/10/24 05:10:46 Dispatch Tribunal
OncoCyte (NYSE:OCX) and Immunomedics (NASDAQ:IMMU) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership. Profitability This table compares OncoCyte and Immunomedics’ net margins, return on equity and return on assets. Net Margins […]
   Gilead Sciences Closes Immunomedics Purchase  2020/10/23 15:47:35 The Street
The two companies announced the $21 billion acquisition last month.
   Gilead Sciences Completes Acquisition of Immunomedics, Inc.  2020/10/23 13:15:00 Business Wire
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (Nasdaq: IMMU) for approximately $21 billion in the aggregate. “We are very pleased to reach today’s milestone and to welcome the talented Immunomedics team to the Gilead family. There is a lot of important work ahead of us to deliver on the vast potential that Trodelvy offers for patients with cancer,” said Daniel O’Day,
   The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO  2020/10/23 11:26:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Kodiak Sciences Inc (NASDAQ: KOD ) Nevro Corp (NYSE: NVRO ) Praxis Precision Medicines Inc (NASDAQ: PRAX ) Repligen Corporation (NASDAQ: RGEN ) Replimune Group Inc (NASDAQ: REPL ) (priced its common stock offering of 4.69 million shares at $40 apiece. Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 22) Artelo Biosciences Inc (NASDAQ: ARTL ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Aziyo Biologics Inc (NASDAQ: AZYO ) DBV Technologies ADR Representing 0.5 Ord Shs (NASDAQ: DBVT ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its $15 million worth of common stock offering) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Metacrine Inc (NASDAQ: MTCR ) Rockwell Medical Inc (NASDAQ: RMTI ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) Stocks In Focus Akebia Presents Positive Phase 3 Data For Anemia Drug In Chronic Kidney Disease Patients Akebia Therapeutics Inc (NASDAQ: AKBA ) presented at the American Society of Nephrology Kidney Week 2020 Reimagined, …
   The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings  2020/10/21 12:04:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20) Aileron Therapeutics Inc (NASDAQ: ALRN ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI )( announced a reverse merger with Cytocom) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Insmed Incorporated (NASDAQ: INSM ) Laboratory Corp. of America Holdings (NYSE: LH ) Pacific Biosciences of California Inc (NASDAQ: PACB ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 19) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Alector Inc (NASDAQ: ALEC ) Aligos Therapeutics Inc (NASDAQ: ALGS ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Baudax Bio Inc (NASDAQ: BXRX ) (issued a corporate update) Codiak BioSciences Inc (NASDAQ: CDAK ) (listed on Nasdaq on Oct. 14) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) ProQR Therapeutics NV (NASDAQ: PRQR ) Titan Pharmaceuticals, Inc (NASDAQ: TTNP ) Stocks In Focus Prothena to Advance Parkinson's Disease Drug Into Large-scale Confirmatory Study Prothena Corporation PLC (NASDAQ: PRTA ) said, based on positive signals of efficacy consistent with disease modification in the PASADENA study, it along with Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ) plans …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 イミュノメディクス IMMU Immunomedics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)